Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus

British Journal of Pharmacology

Volumn 171, Issue 24, 2014, Pages 5636-5649

  Mechlovich, Danit ^a   Amit, Tamar ^a   Bar Am, Orit ^a   Weinreb, Orly ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATECHOLAMINE; DOPAMINE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; INSULIN RECEPTOR; IRON CHELATING AGENT; MONOAMINE; NORADRENALIN; OXIDOREDUCTASE; 5-(N-METHYL-N-PROPARGYLAMINOMETHYL)-8-HYDROXYQUINOLINE; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HIF1A PROTEIN, MOUSE; QUINOLINOL DERIVATIVE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; GLUCOSE TOLERANCE; GLYCOLYSIS; IN VIVO STUDY; LIPID DIET; MALE; METABOLITE; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; BRAIN; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HYDROXYQUINOLINES; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN; IRON CHELATING AGENTS; MICE; MICE, TRANSGENIC; MONOAMINE OXIDASE; NOREPINEPHRINE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INSULIN; SEROTONIN;

EID: 84918781307     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12862     Document Type: Article

References (55)

1. Ahmad W, (2013). Overlapped metabolic and therapeutic links between Alzheimer and diabetes. Mol Neurobiol 47: 399-424.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol, 170, 1676-1705.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol, 170: 1706-1796.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol, 170: 17.
5. Arase K, Fisler JS, Shargill NS, York DA, Bray GA, (1988). Intracerebroventricular infusions of 3-OHB and insulin in a rat model of dietary obesity. Am J Physiol 255 (6 Pt 2): R974-R981.
6. Arnold SE, Lucki I, Brookshire BR, Carlson GC, Browne CA, Kazi H, et al. (2014). High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol Dis 67C: 79-87.
7. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, et al. (2007). Neurorescue activity, APP regulation and amyloid-beta peptide reduction by multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4: 403-411.
8. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MB, Weinreb O, (2010). Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res 7: 300-306.
9. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, et al. (2000). Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67: 577-585.
10. Chavez M, Riedy CA, Van Dijk G, Woods SC, (1996). Central insulin and macronutrient intake in the rat. Am J Physiol 271 (3 Pt 2): R727-R731.
11. Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, et al. (2012). Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res 1441: 64-78.
12. De la Monte SM, Wands JR, (2008). Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2: 1101-1113.
13. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S, (2008). Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 172: 738-747.
14. Gabbay RA, Sutherland C, Gnudi L, Kahn BB, O'Brien RM, Granner DK, et al. (1996). Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem 271: 1890-1897.
15. Gal S, Zheng H, Fridkin M, Youdim MB, (2005). Multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95: 79-88.
16. Gal S, Zheng H, Fridkin M, Youdim MB, (2010). Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 17: 15-27.
17. Ghanim H, Monte SV, Sia CL, Abuaysheh S, Green K, Caruana JA, et al. (2012). Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery. J Clin Endocrinol Metab 97: E1197-E1201.
18. Goldstein BJ, (2002). Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90 (5A): 3G-10G.
19. Green AR, Mitchell BD, Tordoff AF, Youdim MB, (1977). Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 60: 343-349.
20. Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S, (2007). Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101: 757-770.
21. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-904.
22. Hooijmans CR, Graven C, Dederen PJ, Tanila H, van Groen T, Kiliaan AJ, (2007). Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 1181: 93-103.
23. Hou WK, Xian YX, Zhang L, Lai H, Hou XG, Xu YX, et al. (2007). Influence of blood glucose on the expression of glucose trans-porter proteins 1 and 3 in the brain of diabetic rats. Chin Med J (Engl) 120: 1704-1709.
24. Huang XF, Yu Y, Zavitsanou K, Han M, Storlien L, (2005). Differential expression of dopamine D2 and D4 receptor and tyrosine hydroxylase mRNA in mice prone, or resistant, to chronic high-fat diet-induced obesity. Brain Res Mol Brain Res 135: 150-161.
25. Kaczmarczyk MM, Machaj AS, Chiu GS, Lawson MA, Gainey SJ, York JM, et al. (2013). Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice. Psychoneuroendocrinology 38: 1553-1564.
26. Kahn SE, Prigeon RL, Schwartz RS, Fujimoto WY, Knopp RH, Brunzell JD, et al. (2001). Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity. J Nutr 131: 354S-360S.
27. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB, (2009). Neuroprotective and neuritogenic activities of multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23: 3766-3779.
28. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, Youdim MB, (2011). molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 189: 345-358.
29. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O, (2012a). Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 133: 267-274.
30. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O, (2012b). The multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid Redox Signal 17: 860-877.
31. Lee AK, Mojtahed-Jaberi M, Kyriakou T, Astarloa EA, Arno M, Marshall NJ, et al. (2010). Effect of high-fat feeding on expression of genes controlling availability of dopamine in mouse hypothalamus. Nutrition 26: 411-422.
32. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX, (2008). Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582: 359-364.
33. Mechlovich D, Amit T, Bar-Am O, Mandel S, Youdim MB, Weinreb O, (2013). The multi-target iron chelator, M30 Modulates HIF-1alpha-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice. Curr Alzheimer Res 11: 119-127.
34. Moret C, Briley M, (2011). The importance of norepinephrine in depression. Neuropsychiatr Dis Treat 7 (Suppl. 1): 9-13.
35. Morrison CD, Pistell PJ, Ingram DK, Johnson WD, Liu Y, Fernandez-Kim SO, et al. (2010). High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. J Neurochem 114: 1581-1589.
36. Naoi M, Maruyama W, (2009). Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 9: 1233-1250.
37. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
38. Puig KL, Floden AM, Adhikari R, Golovko MY, Combs CK, (2012). Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat diet-induced obesity. PLoS ONE 7: e30378.
39. Roberts RE, Deleger S, Strawbridge WJ, Kaplan GA, (2003). Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes Relat Metab Disord 27: 514-521.
40. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, et al. (2002). An iron-responsive element type II in the 5-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277: 45518-45528.
41. Sayre LM, Smith MA, Perry G, (2001). Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8: 721-738.
42. Scheepers A, Joost HG, Schurmann A, (2004). The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 28: 364-371.
43. Semenza GL, (2000). Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 59: 47-53.
44. Shemyakov SE, (2001). Monoamine oxidase activity, lipid peroxidation, and morphological changes in human hypothalamus during aging. Bull Exp Biol Med 131: 586-588.
45. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, et al. (2005). Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280: 41732-41743.
46. Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, et al. (2006). Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 63: 824-830.
47. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. (2010). Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107: 7036-7041.
48. Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, et al. (2008). High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem 106: 475-485.
49. Vucetic Z, Carlin JL, Totoki K, Reyes TM, (2012). Epigenetic dysregulation of the dopamine system in diet-induced obesity. J Neurochem 120: 891-898.
50. Weinreb O, Amit T, Bar-Am O, Youdim MB, (2010). Rasagiline: a anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 92: 330-344.
51. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, et al. (2011). Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 152: 2634-2643.
52. Youdim MB, Bakhle YS, (2006). Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 (Suppl. 1): S287-S296.
53. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, et al. (1999). Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19: 9821-9830.
54. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, et al. (2005a). multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95: 68-78.
55. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, et al. (2005b). Design, synthesis, and evaluation of bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13: 773-783.